Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas," Mexico City, Mexico.
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico.
J Interferon Cytokine Res. 2022 Aug;42(8):369-392. doi: 10.1089/jir.2022.0029. Epub 2022 Jun 7.
Emerging respiratory viruses are major health threats due to their potential to cause massive outbreaks. Over the past 2 years, the coronavirus disease 2019 (COVID-19) pandemic has caused millions of cases of severe infection and deaths worldwide. Although natural and vaccine-induced protective immune mechanisms against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been increasingly identified, the factors that determine morbimortality are less clear. Comparing the immune signatures of COVID-19 and other severe respiratory infections such as the pandemic influenza might help dissipate current controversies about the origin of their severe manifestations. As such, identifying homologies in the immunopathology of both diseases could provide targets for immunotherapy directed to block shared pathogenic mechanisms. Meanwhile, finding unique characteristics that differentiate each infection could shed light on specific immune alterations exploitable for diagnostic and individualized therapeutics for each case. In this study, we summarize immunopathological aspects of COVID-19 and pandemic influenza from the perspective of cytokine storms as the driving force underlying morbidity. Thereby, we analyze similarities and differences in the cytokine profiles of both infections, aiming to bring forward those molecules more attractive for translational medicine and drug development.
新兴呼吸道病毒是主要的健康威胁,因为它们有可能导致大规模爆发。在过去的 2 年中,新型冠状病毒病(COVID-19)大流行在全球范围内导致了数百万人的严重感染和死亡。尽管针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的天然和疫苗诱导的保护性免疫机制已逐渐被识别,但决定发病率和死亡率的因素尚不清楚。比较 COVID-19 和其他严重呼吸道感染(如大流行性流感)的免疫特征可能有助于消除目前关于其严重表现起源的争议。因此,确定这两种疾病的免疫病理学中的同源性可为针对共同致病机制的免疫治疗提供靶点。同时,发现区分每种感染的独特特征可以阐明可用于每种病例的诊断和个体化治疗的特定免疫改变。在这项研究中,我们从细胞因子风暴作为导致发病的驱动力的角度总结了 COVID-19 和大流行性流感的免疫病理学方面。从而,我们分析了这两种感染的细胞因子谱的相似性和差异,旨在提出那些更适合转化医学和药物开发的分子。